Medpace Holdings (MEDP) Price & Analysis

Compare

648 Followers

MEDP Stock Chart & Stats

$568.53

$7.21(2.08%)

At close: Jan 08 4:00 PM EST

$568.53

$7.21(2.08%)

Day’s Range― - ―

52-Week Range$250.05 - $628.92

Previous CloseN/A

Volume64.09K

Average Volume (3M)184.97K

Market Cap

$16.57B

Enterprise Value$15.87B

Total Cash (Recent Filing)$285.35M

Total Debt (Recent Filing)$143.97M

Price to Earnings (P/E)39.8

Beta1.14

Next Earnings

Feb 09, 2026

EPS Estimate

4.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.86

Shares Outstanding28,168,222

10 Day Avg. Volume219,960

30 Day Avg. Volume184,975

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)12.46

Price to Sales (P/S)4.88

P/FCF Ratio17.97

Enterprise Value/Market Cap0.96

Enterprise Value/Revenue6.73

Enterprise Value/Gross Profit21.64

Enterprise Value/Ebitda30.48

Forecast

1Y Price Target

$585.00

Price Target Upside2.90% Upside

Rating ConsensusHold

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Guidance-driven Revenue AccelerationA recent inflection in bookings and revenue coupled with constructive guidance points to accelerating top-line momentum that may boost investor confidence.

Record New BusinessRecord net new business and improving bookings relative to billed work indicate strong commercial momentum and an expanding sales pipeline that could drive future revenue.

SMid-biotech Client FocusHeavy exposure to SMid-sized biotech clients positions the company to capture faster growth in that end market and supports the case for a valuation premium.

Bears Say

Backlog Conversion UncertaintySustaining unusually high backlog conversion and booking rates may be uncertain amid tepid biotech funding, creating execution risk to projected revenue trends.

Margin Pressure From HiringA re-acceleration in hiring could pressure margins as operating costs rise before revenue gains are realized.

Valuation RiskElevated valuation multiples leave limited downside cushion if biotech funding or macro conditions weaken, increasing share-price sensitivity to execution misses.

Medpace Holdings News

Medpace price target raised to $660 from $655 at Mizuho

Mizuho raised the firm’s price target on Medpace (MEDP) to $660 from $655 and keeps an Outperform rating...

26d ago

MEDP

Medpace price target raised to $525 from $485 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $525 from $485 and keeps...

2M ago

MEDP

Jefferies says market thinking ‘backwards’ on FDA one trial proposal

Jefferies says the “market’s thinking is backwards” that a single pivotal drug trial for approvals is a risk...

2M ago

IQV

FTRE

FDA shift in drug study requirements sends trial runners lower

Shares of companies that conduct drug trials on behalf of pharmaceutical companies, such as Icon (ICLR), Iqvia (IQV),...

2M ago

AZN

BMY

FDA to reduce number of trials required for drug approvals, STAT reports

The FDA plans to generally require only one clinical study, rather than the traditional two, for medical product...

2M ago

AZN

BMY

Medpace initiated with a Market Perform at BMO Capital

BMO Capital initiated coverage of Medpace (MEDP) with a Market Perform rating and $600 price target The firm...

3M ago

MEDP

Medpace Holdings Inc: Key Update on the OPAL Study for Lymphoid Malignancies

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. The OPAL Study, officially titled ‘An...

3M ago

MEDP

Medpace and AVM Biotechnology’s Promising ARDS Study: A Potential Game Changer

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Medpace Holdings Inc. is collaborating with...

3M ago

MEDP

Medpace and Telix Collaborate on Promising Phase 3 Study for Advanced Kidney Cancer

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Medpace Holdings Inc. is collaborating with...

3M ago

MEDP

Medpace and Radiopharm Launch Promising Cancer Study with 177LuBetaBart

Medpace Holdings Inc (($MEDP)), Radiopharm Theranostics Limited (($AU:RAD)) announced an update on their ongoing clinical study. Medpace Holdings...

3M ago

MEDP

Medpace and Radiopharm Theranostics Advance Brain Metastases Imaging Study

Medpace Holdings Inc (($MEDP)), Radiopharm Theranostics Limited (($AU:RAD)) announced an update on their ongoing clinical study. Medpace Holdings...

3M ago

MEDP

Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study

Medpace Holdings Inc (($MEDP)), Edgewise Therapeutics, Inc. (($EWTX)) announced an update on their ongoing clinical study. Medpace Holdings...

3M ago

EWTX

MEDP

Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF

Tenax Therapeutics (($TENX)), Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Tenax Therapeutics, in...

3M ago

MEDP

TENX

Medpace Holdings Inc: A New Frontier in Carotid Artery Treatment

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Study Overview: The SKYWARD Trans-Carotid IDE...

3M ago

MEDP

MEDP FAQ

What was Medpace Holdings Inc’s price range in the past 12 months?

Medpace Holdings Inc lowest stock price was $250.05 and its highest was $628.91 in the past 12 months.

What is Medpace Holdings Inc’s market cap?

Medpace Holdings Inc’s market cap is $16.57B.

When is Medpace Holdings Inc’s upcoming earnings report date?

Medpace Holdings Inc’s upcoming earnings report date is Feb 09, 2026 which is in 5 days.

How were Medpace Holdings Inc’s earnings last quarter?

Medpace Holdings Inc released its earnings results on Oct 22, 2025. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.535 by $0.325.

Is Medpace Holdings Inc overvalued?

According to Wall Street analysts Medpace Holdings Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medpace Holdings Inc pay dividends?

Medpace Holdings Inc does not currently pay dividends.

What is Medpace Holdings Inc’s EPS estimate?

Medpace Holdings Inc’s EPS estimate is 4.19.

How many shares outstanding does Medpace Holdings Inc have?

Medpace Holdings Inc has 28,168,222 shares outstanding.

What happened to Medpace Holdings Inc’s price movement after its last earnings report?

Medpace Holdings Inc reported an EPS of $3.86 in its last earnings report, beating expectations of $3.535. Following the earnings report the stock price went up 9.121%.

Which hedge fund is a major shareholder of Medpace Holdings Inc?

Currently, no hedge funds are holding shares in MEDP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Medpace Holdings Stock Smart Score

Underperform

Fundamentals

Return on Equity

73.70%

Trailing 12-Months

Asset Growth

-15.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings (MEDP) Earnings & Revenues

Historic Earnings Reports

MEDP Company Deck

MEDP Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue and business growth, with significant net new business awards and a record net book-to-bill ratio. Despite these positive aspects, there were challenges related to a higher effective tax rate, lower interest income, and cancellations. Overall, the call demonstrates a strong performance with some areas for improvement.View all MEDP earnings summaries

MEDP Revenue Breakdown

98.00% U.S.

2.00% Other

MEDP Stock 12 Month Forecast

Average Price Target

$585.00

▲(2.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"296":"$296","661":"$661","387.25":"$387.3","478.5":"$478.5","569.75":"$569.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":660,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$660.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$585.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":525,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$525.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[296,387.25,478.5,569.75,661],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,561.65,569.2153846153846,576.7807692307692,584.3461538461538,591.9115384615385,599.4769230769231,607.0423076923076,614.6076923076923,622.1730769230769,629.7384615384615,637.3038461538462,644.8692307692307,652.4346153846154,{"y":660,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,561.65,563.4461538461538,565.2423076923077,567.0384615384615,568.8346153846154,570.6307692307693,572.4269230769231,574.2230769230769,576.0192307692307,577.8153846153846,579.6115384615384,581.4076923076923,583.2038461538461,{"y":585,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,561.65,558.8307692307692,556.0115384615384,553.1923076923076,550.373076923077,547.5538461538462,544.7346153846154,541.9153846153846,539.0961538461538,536.276923076923,533.4576923076924,530.6384615384616,527.8192307692308,{"y":525,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":332.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":423.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":473.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":587.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":561.65,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >